Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 11, 2012, Pages 2087-2094

  Urban, Nicole ^a   Thorpe, Jason ^a   Karlan, Beth Y ^c   McIntosh, Martin W ^a   Palomares, Melanie R ^d   Daly, Mary B ^e   Paley, Pamela ^b   Drescher, Charles W ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Pacific Gynecology Specialists   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; ETHNICITY; FAMILY HISTORY; FEMALE; GENE MUTATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SMOKING;

ADULT; AGE FACTORS; AGED; ALGORITHMS; CA-125 ANTIGEN; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEINS; RISK FACTORS;

EID: 84869215415     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0616     Document Type: Article

References (32)

1. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700. (Pubitemid 36793054)
2. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374-82.
3. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31:113-9.
4. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 2012;125:65-9.
5. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
6. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5.
7. Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011;412:1447-53.
8. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:228. e1-6.
9. Andersen M, Goff B, Lowe K, Scholler N, Bergan L, Drescher C, et al. Use of a Symptom Index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol 2010;116:378-83.
10. Anderson GL, McIntosh MW, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
11. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365-74.
12. Urban N, Thorpe JD, Bergan L, Forrest R, Kampani A, Scholler N, et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 2011;103:1630-4.
13. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-82.
14. Buys SS, Partridge E, Black A, Johnson CJ, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011;305:2295-303.
15. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206s-10s.
16. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and speci ficity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
17. McIntosh M, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 2003;4:27-40. (Pubitemid 36116886)
18. McIntosh M, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002;11:159-66. (Pubitemid 34202997)
19. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer 2012;130: 1136-44.
20. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011;44:884-8.
21. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012;206:349. e1-7.
22. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121:487-91.
23. Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer 2011;21:852-8.
24. Sato AH, Anderson GL, Urban N, McIntosh MW. Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. Cancer Biomark 2006;2:151-62.
25. Urban N. Designing early detection programs for ovarian cancer. Ann Oncol 2011;22:viii16-8.
26. A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women [updated 2010 Nov 15; cited 2010 Dec 6]. Available from: http://clinicaltrials. gov/ct2/show/NCT01121640.
27. Højsgaard S, Halekoh U, Yan J. The R package geepack for generalized estimating equations. J Stat Softw 2006;15:1-11. (Pubitemid 43037444)
28. Bliese P. Multilevel: multilevel functions. R package version 2.4; 2012 [cited 2012 Jul]. Available from: http://CRAN.R-project.org/package=multilevel.
29. Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2480-7.
30. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009;18:1365-72.
31. Baldwin LM, Trivers KF, Matthews B, Andrilla CH, Miller JW, Berry DL, et al. Vignette-based study of ovarian cancer screening: Do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 2012;156:182-94.
32. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-9. (Pubitemid 41540458)